{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:50:26Z","timestamp":1782481826594,"version":"3.54.5"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020950","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-2628-B075B-001-MY3"],"award-info":[{"award-number":["114-2628-B075B-001-MY3"]}],"id":[{"id":"10.13039\/501100020950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011913","name":"Kaohsiung Veterans General Hospital","doi-asserted-by":"publisher","award":["115-052"],"award-info":[{"award-number":["115-052"]}],"id":[{"id":"10.13039\/501100011913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011913","name":"Kaohsiung Veterans General Hospital","doi-asserted-by":"publisher","award":["-082"],"award-info":[{"award-number":["-082"]}],"id":[{"id":"10.13039\/501100011913","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.canlet.2026.218652","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:48:37Z","timestamp":1780555717000},"page":"218652","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Frontline immunotherapy and immune cold reprogramming across molecular subtypes of advanced endometrial cancer"],"prefix":"10.1016","volume":"655","author":[{"given":"Pei-Hsuan","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hsuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Naveen","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim Jinn-Chyuan","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Jen","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3773-9015","authenticated-orcid":false,"given":"Chia-Jung","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218652_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218652_bib2","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218652_bib3","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218652_bib4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jnci\/djx214","article-title":"International patterns and trends in endometrial cancer incidence, 1978-2013","volume":"110","author":"Lortet-Tieulent","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canlet.2026.218652_bib5","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib6","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1146\/annurev-pathol-020117-043609","article-title":"Molecular genetics of endometrial carcinoma","volume":"14","author":"Bell","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.canlet.2026.218652_bib9","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1136\/ijgc-00009577-200807000-00028","article-title":"Reproducibility of grading systems for endometrial endometrioid carcinoma and their relation with pathologic prognostic parameters","volume":"18","author":"Kapucuoglu","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/PAS.0000000000000764","article-title":"Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on the cancer genome Atlas (TCGA)-based molecular subgroup","volume":"41","author":"Hoang","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.canlet.2026.218652_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.canlet.2026.218652_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.seminoncol.2008.12.006","article-title":"Management of advanced-stage and recurrent endometrial cancer","volume":"36","author":"Ray","year":"2009","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218652_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218652_bib16","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.7150\/jca.120459","article-title":"FIGO staging of endometrial cancer with molecular classification: Dawn and challenges","volume":"16","author":"Zhao","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164101","article-title":"Molecular classification of endometrial cancer and the 2023 FIGO staging: exploring the challenges and opportunities for pathologists","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218652_bib18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-Mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib19","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218652_bib21","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218652_bib22","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218652_bib23","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218652_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071491","article-title":"Detection of microsatellite instability: state of the art and future applications in circulating tumour DNA (ctDNA)","volume":"13","author":"Gilson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218652_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/biom15101370","article-title":"Traditional and new views on MSI-H\/dMMR endometrial cancer","volume":"15","author":"Liu","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.canlet.2026.218652_bib26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1126\/science.aau0447","article-title":"Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response","volume":"364","author":"Mandal","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218652_bib27","article-title":"The role of neoantigens in cancer immunotherapy","volume":"11","author":"Zhu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218652_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2024.01.032","article-title":"The emerging and challenging role of PD-L1 in patients with gynecological cancers: an updating review with clinico-pathological considerations","volume":"184","author":"Santoro","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218652_bib31","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10147-016-0959-z","article-title":"PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues","volume":"21","author":"Hamanishi","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27021096","article-title":"Molecular landscape of advanced endometrial cancer: Exploratory analyses at Modena cancer Center (MEMO)","volume":"27","author":"Pirola","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218652_bib33","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1038\/s41388-018-0303-3","article-title":"Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations","volume":"37","author":"Zerdes","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218652_bib34","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218652_bib35","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/2326-6066.CIR-25-0438","article-title":"TIME for endometrial cancer: advancements and challenges in therapeutic targets for the endometrial cancer tumor immune microenvironment","volume":"13","author":"Pruitt","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218652_bib36","article-title":"The immune microenvironment in endometrial carcinoma: mechanisms and therapeutic targeting","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218652_bib37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094871","article-title":"Vascular endothelial growth factor, a key modulator of the anti-tumor immune response","volume":"22","author":"Geindreau","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218652_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111607","article-title":"Vascular normalization in immunotherapy: a promising mechanisms combined with radiotherapy","volume":"139","author":"Liu","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218652_bib40","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41419-021-04171-z","article-title":"Extracellular vesicles and immunogenic stress in cancer","volume":"12","author":"Wu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218652_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13009","article-title":"Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment","volume":"54","author":"Liu","year":"2021","journal-title":"Cell Prolif."},{"key":"10.1016\/j.canlet.2026.218652_bib42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/14737140.2022.2039123","article-title":"Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies","volume":"22","author":"Motzer","year":"2022","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.canlet.2026.218652_bib43","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s10147-025-02721-5","article-title":"Lenvatinib enhances antitumor immunity of anti-PD-1 antibody","volume":"30","author":"Kato","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104883","article-title":"Combination of immune checkpoint inhibitors and anti-angiogenic agents: an emerging strategy for cancer therapy","volume":"215","author":"Li","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.canlet.2026.218652_bib45","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death Receptor-1 and vascular endothelial growth factor Receptor-2 blockade promotes vascular normalization and enhances Antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218652_bib46","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010541","article-title":"Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer","volume":"13","author":"Roudko","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib48","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218652_bib49","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920944116","article-title":"PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers","volume":"12","author":"Lee","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib50","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus Carboplatin\/Paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib51","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-Deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218652_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114712","article-title":"Targeting PARP for the optimal immunotherapy efficiency in gynecologic malignancies","volume":"162","author":"Li","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218652_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-00336-4","article-title":"PARP inhibitors elicit a cellular senescence mediated inflammatory response in homologous recombination proficient cancer cells","volume":"15","author":"Kamii","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218652_bib54","article-title":"The molecular classification ushers in a new era for the treatment of advanced and recurrent endometrial cancer","volume":"15","author":"Yan","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib55","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1172\/JCI84940","article-title":"Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer","volume":"126","author":"Mehnert","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218652_bib56","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1186\/s12885-024-13058-z","article-title":"Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012190","article-title":"Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants","volume":"13","author":"Maddalena","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-Cell-Inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib59","article-title":"Biomarkers and immunotherapy in endometrial cancer: mechanisms and clinical applications","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218652_bib60","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00262-025-03980-x","article-title":"Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacy","volume":"74","author":"Landre","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218652_bib61","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00280-010-1384-z","article-title":"Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin","volume":"67","author":"Ueda","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218652_bib62","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2024.12.020","article-title":"Pembrolizumab in microsatellite instability-high\/mismatch repair deficient (MSI-H\/dMMR) and non-MSI-H\/non-dMMR advanced endometrial cancer: phase 2 KEYNOTE-158 study results","volume":"193","author":"O'Malley","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib63","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 Study","volume":"40","author":"O'Malley","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib64","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET Study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218652_bib65","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1136\/ijgc-2022-004178","article-title":"Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent\/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England","volume":"33","author":"Goulden","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"Oaknin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14238366","article-title":"A new direction in endometrial cancer Therapy-PD-1 and PD-L1 immune checkpoint inhibitors-where will it take Us?","volume":"14","author":"Mielnicka","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2026.218652_bib68","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib69","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2026.218652_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115329","article-title":"Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: a systematic review and network meta-analysis","volume":"220","author":"Villacampa","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib71","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1186\/s12885-025-15039-2","article-title":"Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib72","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.051","article-title":"LBA39 Final overall survival (OS) results from the randomized double-blind phase III AtTEnd\/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced\/recurrent endometrial cancer","volume":"36","author":"Ginesta","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14041385","article-title":"Comprehensive review of endometrial cancer: new molecular and FIGO classification and recent treatment changes","volume":"14","author":"Anca-Stanciu","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canlet.2026.218652_bib75","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218652_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32060340","article-title":"Updated Guidelines for the diagnosis and treatment of endometrial carcinoma: the Polish Society of gynecological oncology","volume":"32","author":"Sznurkowski","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2025.110275","article-title":"Molecular evolution of driver mutations in cancer with microsatellite instability and their impact on tumor progression: implications for precision medicine in patients with UCEC","volume":"192","author":"Sriramadasu","year":"2025","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.canlet.2026.218652_bib78","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218652_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101656","article-title":"Circulating tumor DNA in endometrial cancer: clinical significance and implications","volume":"35","author":"Capasso","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2024.100151","article-title":"Unlocking the promise of liquid biopsies in precision oncology","volume":"3","author":"Pando-Caciano","year":"2024","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.canlet.2026.218652_bib81","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2025.03.006","article-title":"The genomic landscape of distant metastatic endometrial cancer","volume":"195","author":"Zammarrelli","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib82","first-page":"273","article-title":"[Vascular normalization and cancer immunotherapy]","volume":"17","author":"Zeng","year":"2014","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"10.1016\/j.canlet.2026.218652_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007929","article-title":"Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111\/KEYNOTE-146","volume":"12","author":"Makker","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib84","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III Study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib85","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2023.03.015","article-title":"Health-Related quality of life in patients with advanced endometrial cancer treated with lenvatinib plus pembrolizumab or treatment of physician's choice","volume":"186","author":"Lorusso","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2024.05.006","article-title":"Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: a systematic review and meta-analysis","volume":"187","author":"Kim","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2024.10.008","article-title":"Real world outcomes in patients with recurrent, advanced, or metastatic endometrial cancer treated with lenvatinib plus pembrolizumab","volume":"37","author":"Pawsey","year":"2025","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1622253","article-title":"Toxicity and efficacy of lenvatinib plus pembrolizumab in advanced endometrial cancer: a real-world retrospective analysis","volume":"15","author":"Barbi","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib89","first-page":"283","article-title":"Durvalumab plus Carboplatin\/Paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer","volume":"42","author":"Westin","year":"2024","journal-title":"The Phase III DUO-E Trial"},{"key":"10.1016\/j.canlet.2026.218652_bib90","doi-asserted-by":"crossref","first-page":"S557","DOI":"10.1016\/j.annonc.2024.08.794","article-title":"732P Durvalumab + carboplatin\/paclitaxel (CP) followed by durvalumab \u00b1 olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E","volume":"35","author":"Blank","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib91","article-title":"Targeting HDAC and PARP enhances STING-Dependent antitumor immunity in STING-Deficient tumor","volume":"12","author":"Mao","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.canlet.2026.218652_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002255","article-title":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial","volume":"9","author":"Antill","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1668406","article-title":"Real-world outcomes of immune checkpoint inhibitor-based combination therapy in older adult patients with metastatic renal cell carcinoma: a multi-center, retrospective analysis","volume":"16","author":"Ikoma","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218652_bib94","doi-asserted-by":"crossref","first-page":"293","DOI":"10.18295\/squmj.9.2023.057","article-title":"Managing the adverse events associated with pembrolizumab and lenvatinib therapy in endometrial cancer","volume":"24","author":"Zribi","year":"2024","journal-title":"Sultan Qaboos Univ Med J"},{"key":"10.1016\/j.canlet.2026.218652_bib95","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s44276-025-00145-2","article-title":"Next-generation sequencing outperforms Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) in endometrial cancer molecular classification","volume":"3","author":"Yoshimura","year":"2025","journal-title":"BJC Rep"},{"key":"10.1016\/j.canlet.2026.218652_bib96","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1200\/JCO-24-01326","article-title":"First-Line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: a randomized, Open-Label, phase III trial","volume":"43","author":"Marth","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-015-0020-3","article-title":"Immunotherapy in endometrial cancer - an evolving therapeutic paradigm","volume":"2","author":"Longoria","year":"2015","journal-title":"Gynecol Oncol Res Pract"},{"key":"10.1016\/j.canlet.2026.218652_bib98","article-title":"Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib99","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101797","article-title":"Precision oncology in endometrial cancer: closing the gap between potential and practice","volume":"35","author":"Podder","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib101","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ijgc-2022-003675","article-title":"Immunotherapy in endometrial cancer","volume":"33","author":"Mahdi","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib102","article-title":"Unveiling immunogenic characteristics and neoantigens in endometrial cancer with POLE hotspot mutations for improved immunotherapy","volume":"16","author":"Huang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218652_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1596879","article-title":"Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma","volume":"15","author":"Cai","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib104","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218652_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.955979","article-title":"The IFN-gamma-related long non-coding RNA signature predicts prognosis and indicates immune microenvironment infiltration in uterine corpus endometrial carcinoma","volume":"12","author":"Gu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib106","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218652_bib107","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1013463","article-title":"The association of Wnt-signalling and EMT markers with clinical characteristics in women with endometrial cancer","volume":"13","author":"Ledinek","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040889","article-title":"Wnt\/beta-Catenin signaling and immunotherapy resistance: lessons for the treatment of urothelial carcinoma","volume":"13","author":"Chehrazi-Raffle","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218652_bib109","article-title":"Immunotherapy in endometrial cancer: mechanisms, clinical evidence, and future directions","volume":"16","author":"Lian","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218652_bib110","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41388-022-02221-0","article-title":"Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression","volume":"41","author":"Mota","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218652_bib111","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CJI.0000000000000417","article-title":"B2M and JAK1\/2-mutated MSI-H colorectal carcinomas can benefit from Anti-PD-1 therapy","volume":"45","author":"Zhang","year":"2022","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2026.218652_bib112","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12962-025-00625-9","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer: a cost-effectiveness analysis","volume":"23","author":"Zhao","year":"2025","journal-title":"Cost Eff. Resour. Allocation"},{"key":"10.1016\/j.canlet.2026.218652_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953115","article-title":"Targeting immunometabolism mediated by the IDO1 Pathway: a new mechanism of immune resistance in endometrial cancer","volume":"13","author":"Passarelli","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218652_bib114","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2026.218652_bib115","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ijgo.70280","article-title":"Immune checkpoint inhibitors in gynecologic oncology: current status and perspectives","volume":"171","author":"Yanaihara","year":"2025","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.canlet.2026.218652_bib116","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1136\/ijgc-2023-004454","article-title":"Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: when is hormonal-based therapy the preferred option?","volume":"33","author":"Mahdi","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib117","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218652_bib118","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune Checkpoint Inhibitor Therapy: ASCO Guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib119","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib120","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib121","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00262-024-03772-9","article-title":"Negative association of steroids with immunotherapy efficacy in a multi-tumor cohort: time and dose-dependent","volume":"73","author":"Albarran","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218652_bib122","first-page":"1515","article-title":"Current status of management of immune-related adverse events and practical needs for oncologist education","volume":"22","author":"Tian","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.canlet.2026.218652_bib123","article-title":"Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis","volume":"14","author":"O'Reilly","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib124","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10147-025-02951-7","article-title":"Real-world safety and efficacy of immune checkpoint inhibitors in Japanese patients with persistent, recurrent, or metastatic cervical cancer: a multicenter prospective and retrospective study","volume":"31","author":"Kitami","year":"2026","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib125","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241277656","article-title":"Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO\/GOG-3031\/RUBY)","volume":"16","author":"Auranen","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib126","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.annonc.2023.09.1927","article-title":"748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309\/KEYNOTE-775","volume":"34","author":"Colomba","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib127","volume":"35","author":"Valabrega","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2026.218652_bib128","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/spcare-2024-005107","article-title":"Digital health for cancer symptom management in palliative medicine: systematic review","volume":"14","author":"Hamdoune","year":"2024","journal-title":"BMJ Support. Palliat. Care"},{"key":"10.1016\/j.canlet.2026.218652_bib129","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2025.12.003","article-title":"Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors - a single centre experience","volume":"204","author":"Fernandes","year":"2026","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2026.218652_bib130","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1007\/s12325-019-01051-z","article-title":"Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors","volume":"36","author":"Arora","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.canlet.2026.218652_bib131","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ygyno.2024.04.008","article-title":"Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): a critical reappraisal with comments on FIGO 2023 staging","volume":"186","author":"Espinosa","year":"2024","journal-title":"Gynecol. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:17:48Z","timestamp":1782479868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":131,"alternative-id":["S0304383526004155"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218652","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frontline immunotherapy and immune cold reprogramming across molecular subtypes of advanced endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218652","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218652"}}